Advocating for Demonstration of Disease Modification in Trials of Drugs for Early AD

This Viewpoint discusses the benefits of clinical trials with a delayed-start design and analysis of downstream biomarkers to examine whether antimyeloid immunotherapy changes the course of early Alzheimer disease.
Source: JAMA Neurology - Category: Neurology Source Type: research